Advertisement

ADVERTISEMENT

Jolynn Tumolo

News
Investigational Oral Agent Significantly Reduces Alzheimer Disease Biomarkers
10/14/2022
After 12 months of treatment with investigational oral agent ALZ-801 (valiltramiprosate), patients with early Alzheimer disease demonstrated statistically significant and clinically relevant plasma biomarker reduction.
After 12 months of treatment with investigational oral agent ALZ-801 (valiltramiprosate), patients with early Alzheimer disease demonstrated statistically significant and clinically relevant plasma biomarker reduction.
After 12 months of treatment...
10/14/2022
Neurology
News
Treatment May Hasten Viral Clearance in Specific Subgroups Hospitalized With COVID-19
11/03/2022
A broad-spectrum antiviral medication was associated with a decreased time to viral clearance in certain patient populations, according to new findings. 
A broad-spectrum antiviral medication was associated with a decreased time to viral clearance in certain patient populations, according to new findings. 
A broad-spectrum antiviral...
11/03/2022
First Report Managed Care
News
Psychoactive Drug Schedule Classification Out of Sync With Psychiatrist Views
11/22/2022
Nonprescribed use of methamphetamine and alprazolam "more concerning" and less acceptable than nonprescribed use of psilocybin and ketamine.
Nonprescribed use of methamphetamine and alprazolam "more concerning" and less acceptable than nonprescribed use of psilocybin and ketamine.
Nonprescribed use of...
11/22/2022
Psych Congress Network
News
Memory, Fluency Most Impaired Cognitive Domains in Patients With MS
12/15/2022
Depression, education, and several other factors were identified as predictors of cognitive dysfunction in patients with multiple sclerosis.
Depression, education, and several other factors were identified as predictors of cognitive dysfunction in patients with multiple sclerosis.
Depression, education, and...
12/15/2022
First Report Managed Care
News
Polypharmacy in Psoriatic Arthritis Linked With Poorer Quality of Life
09/02/2022
“Although physical function was not associated with polypharmacy, patients with major polypharmacy had poorer quality of life,” wrote researchers.
“Although physical function was not associated with polypharmacy, patients with major polypharmacy had poorer quality of life,” wrote researchers.
“Although physical function was...
09/02/2022
First Report Managed Care
News
Migraine Drug Recalled
11/05/2021
The FDA has issued a Class III recall for rizatriptan tablets.
The FDA has issued a Class III recall for rizatriptan tablets.
The FDA has issued a Class III...
11/05/2021
Pharmacy Learning Network
News
Hypotension Injections Recalled
03/09/2023
A recall has been issued for more than 1 million bottles of norepinephrine bitartrate distributed throughout the United States.
A recall has been issued for more than 1 million bottles of norepinephrine bitartrate distributed throughout the United States.
A recall has been issued for...
03/09/2023
Pharmacy Learning Network
News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
Doctor examining a CT scan
News
Older Age Linked With Lower Risk of MS Activity After Stopping DMT
05/08/2023
A patient’s age at discontinuation of first-line disease-modifying therapy (DMT) was a significant predictor of the return of inflammatory disease activity and relapse among patients with multiple sclerosis (MS), according to study results...
A patient’s age at discontinuation of first-line disease-modifying therapy (DMT) was a significant predictor of the return of inflammatory disease activity and relapse among patients with multiple sclerosis (MS), according to study results...
A patient’s age at...
05/08/2023
Neurology
Psilocybin mushrooms in a lab setting
News
Psilocybin Improves Treatment-Resistant Depression Regardless of Antidepressant Status
06/05/2023
Discontinuing antidepressants did not hamper the effect of synthetic psilocybin for treatment-resistant depression. Researchers reported the findings at the 2023 American Psychiatric Association Annual Meeting.
Discontinuing antidepressants did not hamper the effect of synthetic psilocybin for treatment-resistant depression. Researchers reported the findings at the 2023 American Psychiatric Association Annual Meeting.
Discontinuing antidepressants...
06/05/2023
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use